Faculty

Steven Pergam

Adjunct Professor, Epidemiology
Professor, Medicine - Allergy and Infectious Dis.


Education

MD University of Nebraska, 1998
MPH Epidemiology, University of Washington, 2008

Contact


Fred Hutch Cancer Center
Box 358080
1100 Fairview Ave. N, E4-100
Seattle, WA 98109
View Website »

Bio

Dr. Pergam is an Infectious Diseases physician and researcher who received his MD from the University of Nebraska School of Medicine, his Infectious Diseases fellowship training at the University of Washington (UW), and his MPH from the UW School of Public Health. Dr. Pergam serves as the Medical Director of Infection Prevention at the Seattle Cancer Care Alliance (SCCA). Dr. Pergam focuses his research on the prevention and treatment of infections among immunocompromised patients, and has expertise in infection prevention and hospital epidemiology among cancer and transplant patients. He serves on numerous national committees, including the CDC’s Advisory Committee on Immunization Practices, and the National Comprehensive Cancer Network Committee on the Prevention and Treatment of Infections in Cancer. He also is an Associate Editor for BMC Infectious Diseases and Current Opinions in Infectious Diseases.

Research Areas

Research Interests

Dr. Pergam’s research interests involve hospital epidemiology, antimicrobial resistance, and infection prevention in immunosuppressed hosts. His research group focuses on infection prevention, resistant pathogens, antimicrobial stewardship, and on the development of novel prevention strategies for community and healthcare-associated infections in cancer and hematopoietic cell transplant patients. He has active research projects that evaluate vaccinations, water-borne pathogens, resistant bacteria, respiratory virus transmission, and fungal infections among immunocompromised hosts. He is interested in the interplay between the immune response, the microbiome, bacterial and viral infections in the respiratory and gastrointestinal systems, and their association with inflammatory complications (e.g. Graft-versus-host disease, mucositis).

Recent Publications (PubMed)

Limited yield of SARS-CoV-2 screening in asymptomatic hematopoietic cell transplant and chimeric antigen receptor T-cell therapy patients.
(2025)
Antimicrob Steward Healthc Epidemiol 5(1): e195
Wilson MH, Krantz EM, Pergam SA, Mielcarek M, Elgar S, Rosen E, Swetky M, Liu C, Hill JA, Cohen S, McCulloch DJ
A Network for Advancing Prevention and Treatment of Infections Among Immunocompromised Individuals.
(2025 Aug 1)
JAMA Netw Open 8(8): e2528383
Hill JA, Pergam SA, Halasa NB, Kumar D, Baden LR, Boeckh MJ
The smallest faith.
(2025 Aug 11)
Lancet Infect Dis
Pergam SA
Risk Factors for COVID-19-Related Hospitalization and Death in Patients With Cancer: The National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS).
(2025 Sep 1)
JAMA Oncol 11(9): 990-998
Rini BI, Best AF, Bowman MD, Mishkin GE, Denicoff AM, Rubinstein LV, Harris L, Geiger AM, Mark NM, Pergam SA, Warner JL, Khorana AA, Gnjatic S, Yen TWF, Liles DK, Bestvina CM, Shah NJ, Norrell JT, Hershman DL, Holter-Chakrabarty JL, Poklepovic AS, Chanock SJ, Sankaran H, Korde LA
T Cell Immune Response to Influenza Vaccination When Administered Prior to and Following Autologous Chimeric Antigen Receptor-Modified T Cell Therapy.
(2025 May)
Transplant Cell Ther 31(5): 327-338
Kinoshita H, Walti CS, Webber K, Pezzella G, Jensen-Wachspress M, Lang H, Shuey K, Boonyaratanakornkit J, Pergam SA, Chu HY, Bollard CM, Keller MD, Hill JA
Show complete publication list